loratadine has been researched along with Sensitivity and Specificity in 25 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The method was shown to be accurate, rapid and sufficiently sensitive to be successfully applied to a pharmacokinetic and bioequivalent study." | 2.73 | Simultaneous determination of desloratadine and its active metabolite 3-hydroxydesloratadine in human plasma by LC/MS/MS and its application to pharmacokinetics and bioequivalence. ( Chen, WL; Chu, NN; Li, XN; Xu, HR, 2007) |
| "A rapid, sensitive, and accurate bioanalytical method was established for the quantitation and pharmacokinetic investigation of loratadine (LTD) in rat plasma by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS) using loratadine-d5 as internal standard (ISTD)." | 1.43 | LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ( Singh, SK; Verma, S, 2016) |
| " The method was successfully applied to a pharmacokinetic study of RT and its two metabolite DT and 3-OH-DT in healthy volunteers following single (10, 20, 40 mg) and multiple (10 mg) oral doses of rupatadine fumarate tablets." | 1.42 | Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study. ( Ding, L; Gu, P; Li, Q; Liu, B; Pan, L; Sun, C; Wu, C; Zhang, J, 2015) |
| " The method has been successfully applied to a pharmacokinetic study of rupatadine and its major metabolite after oral administration of 10, 20 and 40mg rupatadine tablets to healthy Chinese volunteers." | 1.35 | Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers. ( Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y, 2009) |
| "Inter- and intra-individual variability of the loratadine (LOR) metabolism in Caucasian subjects was assessed during a bioequivalence study for two pharmaceutical formulations (solid oral dosage forms) containing 10 mg of the active substance." | 1.34 | Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. ( David, V; Medvedovici, A; Sora, DI; Udrescu, S, 2007) |
| "To support the pharmacokinetic and bioavailability study of an extended-release loratadine (LOR)/pseudoephedrine sulfate (PES) tablet, a high performance liquid chromatographic-electrospray ionisation-mass spectrometric method (LC-MS) was developed for the simultaneous determination of LOR and PES in human plasma." | 1.33 | Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ( Gu, Y; Huang, M; Li, H; Shao, F; Sun, J; Wang, G; Wang, W; Xie, H; Zhang, J; Zhang, Q; Zhao, S, 2005) |
| "Desloratadine is a non-sedating, clinically effective, anti-allergic therapy that has been shown to exhibit anti-inflammatory properties that extend beyond its ability to antagonize histamine at H(1)-receptor sites." | 1.31 | Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. ( Kreutner, W; Lichtenstein, LM; Schleimer, RP; Schroeder, JT, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Ebrahimzadeh, H | 1 |
| Molaei, K | 1 |
| Asgharinezhad, AA | 1 |
| Shekari, N | 1 |
| Dehghani, Z | 1 |
| Ibrahim, FA | 1 |
| El-Enany, N | 1 |
| El-Shaheny, RN | 1 |
| Mikhail, IE | 1 |
| Sun, C | 1 |
| Li, Q | 1 |
| Pan, L | 1 |
| Liu, B | 1 |
| Gu, P | 1 |
| Zhang, J | 2 |
| Ding, L | 1 |
| Wu, C | 1 |
| Verma, S | 1 |
| Singh, SK | 1 |
| Chen, G | 1 |
| Daaro, I | 1 |
| Pramanik, BN | 1 |
| Piwinski, JJ | 1 |
| Wen, J | 1 |
| Hong, Z | 1 |
| Wu, Y | 2 |
| Wei, H | 1 |
| Fan, G | 1 |
| Patel, BN | 1 |
| Sharma, N | 1 |
| Sanyal, M | 1 |
| Shrivastav, PS | 1 |
| Ismaiel, OA | 1 |
| Zhang, T | 1 |
| Jenkins, RG | 1 |
| Karnes, HT | 1 |
| Yang, L | 2 |
| Amad, M | 1 |
| Winnik, WM | 1 |
| Schoen, AE | 1 |
| Schweingruber, H | 1 |
| Mylchreest, I | 1 |
| Rudewicz, PJ | 2 |
| Radhakrishna, T | 1 |
| Narasaraju, A | 1 |
| Ramakrishna, M | 1 |
| Satyanarayana, A | 1 |
| Reddy, KV | 1 |
| Babu, JM | 1 |
| Kumar, YR | 1 |
| Reddy, SV | 1 |
| Kumar, MK | 1 |
| Eswaraiah, S | 1 |
| Reddy, KR | 1 |
| Reddy, MS | 1 |
| Bhaskar, BV | 1 |
| Dubey, PK | 1 |
| Vyas, K | 1 |
| Clement, RP | 2 |
| Kantesaria, B | 1 |
| Reyderman, L | 1 |
| Beaudry, F | 1 |
| Grandmaison, C | 1 |
| Di Donato, L | 1 |
| Masse, R | 1 |
| Yin, OQ | 1 |
| Shi, X | 1 |
| Chow, MS | 1 |
| Sun, J | 1 |
| Wang, G | 1 |
| Wang, W | 1 |
| Zhao, S | 1 |
| Gu, Y | 1 |
| Huang, M | 1 |
| Shao, F | 1 |
| Li, H | 1 |
| Zhang, Q | 1 |
| Xie, H | 1 |
| Vlase, L | 1 |
| Imre, S | 1 |
| Muntean, D | 1 |
| Leucuta, SE | 1 |
| Nirogi, RV | 1 |
| Kandikere, VN | 1 |
| Mudigonda, K | 1 |
| Maurya, S | 1 |
| Sora, DI | 1 |
| Udrescu, S | 1 |
| David, V | 1 |
| Medvedovici, A | 1 |
| Shen, JX | 1 |
| Xu, Y | 1 |
| Tama, CI | 1 |
| Merka, EA | 1 |
| Hayes, RN | 1 |
| Xu, HR | 1 |
| Li, XN | 1 |
| Chen, WL | 1 |
| Chu, NN | 1 |
| Srinubabu, G | 1 |
| Patel, RS | 1 |
| Shedbalkar, VP | 1 |
| Rao, AA | 1 |
| Rao, MN | 1 |
| Bandaru, VV | 1 |
| Motolese, A | 1 |
| Ferdani, G | 1 |
| Manzini, BM | 1 |
| Seidenari, S | 1 |
| Johnson, R | 1 |
| Christensen, J | 1 |
| Lin, CC | 1 |
| Martens, J | 1 |
| Schroeder, JT | 1 |
| Schleimer, RP | 1 |
| Lichtenstein, LM | 1 |
| Kreutner, W | 1 |
1 trial available for loratadine and Sensitivity and Specificity
| Article | Year |
|---|---|
Simultaneous determination of desloratadine and its active metabolite 3-hydroxydesloratadine in human plasma by LC/MS/MS and its application to pharmacokinetics and bioequivalence.
Topics: Administration, Oral; Chromatography, Liquid; Cross-Over Studies; Drug Stability; Humans; Loratadine | 2007 |
24 other studies available for loratadine and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Molecularly imprinted nano particles combined with miniaturized homogenous liquid-liquid extraction for the selective extraction of loratadine in plasma and urine samples followed by high performance liquid chromatography-photo diode array detection.
Topics: Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Loratadine; Molecular Imprin | 2013 |
Simultaneous determination of desloratadine and montelukast sodium using second-derivative synchronous fluorescence spectrometry enhanced by an organized medium with applications to tablets and human plasma.
Topics: Acetates; Calibration; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Cyclopropanes; Huma | 2015 |
Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study.
Topics: Chromatography, Liquid; Cyproheptadine; Female; Formates; Humans; Loratadine; Male; Plasma; Reproduc | 2015 |
LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™.
Topics: Animals; Chromatography, Liquid; Computer Simulation; Drug Delivery Systems; Emulsions; Histamine H1 | 2016 |
Structural characterization of in vitro rat liver microsomal metabolites of antihistamine desloratadine using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange HR-LC/MS.
Topics: Animals; Chromatography, Liquid; Cyclic N-Oxides; Histamine H1 Antagonists, Non-Sedating; Liver; Lor | 2009 |
Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Topics: Adult; Asian People; Calibration; Chromatography, Liquid; Cyproheptadine; Drug Stability; Female; Fo | 2009 |
LC-MS-ESI for the determination of loratadine and descarboethoxyloratadine in human plasma.
Topics: Chromatography, Liquid; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Piperidine | 2010 |
Investigation of endogenous blood plasma phospholipids, cholesterol and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography/mass spectrometry.
Topics: Chemical Fractionation; Chlorpheniramine; Cholesterol; Chromatography, Liquid; Erythrocytes; Glyceri | 2010 |
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays.
Topics: Calibration; Chromatography, High Pressure Liquid; Loratadine; Mometasone Furoate; Pharmaceutical Pr | 2002 |
Simultaneous determination of montelukast and loratadine by HPLC and derivative spectrophotometric methods.
Topics: Acetates; Anti-Asthmatic Agents; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; H | 2003 |
Impurity profile study of loratadine.
Topics: Chromatography, High Pressure Liquid; Drug Contamination; Histamine H1 Antagonists, Non-Sedating; Lo | 2003 |
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.
Topics: Automation; Calibration; Chromatography, Liquid; Humans; Loratadine; Mass Spectrometry; Reproducibil | 2003 |
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.
Topics: Chromatography, High Pressure Liquid; Histamine H1 Antagonists; Humans; Loratadine; Reproducibility | 2003 |
Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies.
Topics: Calibration; Chromatography, High Pressure Liquid; Ephedrine; Histamine H1 Antagonists; Humans; Lora | 2005 |
Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection.
Topics: Calibration; Chromatography, Liquid; Drug Stability; Freezing; Histamine H1 Antagonists, Non-Sedatin | 2007 |
Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard.
Topics: Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Galantamine; Humans; Loratadine; Re | 2007 |
Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies.
Topics: Administration, Oral; Adolescent; Adult; Chromatography, High Pressure Liquid; Drug Stability; Femal | 2007 |
Simultaneous determination of desloratadine and pseudoephedrine in human plasma using micro solid-phase extraction tips and aqueous normal-phase liquid chromatography/tandem mass spectrometry.
Topics: Blood Chemical Analysis; Chromatography, High Pressure Liquid; Complex Mixtures; Ephedrine; Humans; | 2007 |
Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of loratadine and desloratadine in human plasma.
Topics: Chromatography, Liquid; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Reference Standa | 2007 |
Echographic evaluation of patch test inhibition by oral antihistamine.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Loratadine; Male; Middle Aged; Nickel; Patc | 1995 |
Sensitive gas-liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using a nitrogen-phosphorus detector.
Topics: Child; Chromatography, Gas; Female; Humans; Hydrogen-Ion Concentration; Loratadine; Male; Nitrogen; | 1994 |
Determination of loratadine and pheniramine from human serum by gas chromatography-mass spectrometry.
Topics: Gas Chromatography-Mass Spectrometry; Histamine H1 Antagonists; Humans; Kinetics; Loratadine; Microc | 1995 |
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.
Topics: Basophils; Cell Culture Techniques; Cytokines; Dose-Response Relationship, Drug; Gene Expression; Hi | 2001 |